Imbria Pharmaceuticals develops therapies aimed at enhancing or restoring cellular energy production, addressing energy deficits in various medical conditions. Their lead candidate, Ninerafaxstat, is currently being evaluated in clinical trials for its efficacy in treating hypertrophic cardiomyopathy.
Funding
$85.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many medical conditions are characterized by impaired cellular energy production, leading to energy deficits that exacerbate disease pathology. Current treatments often fail to directly address these underlying metabolic deficiencies.
Solution
Imbria Pharmaceuticals is developing therapies designed to enhance or restore cellular energy production, directly targeting the metabolic roots of various diseases. Their lead candidate, Ninerafaxstat, is being evaluated in clinical trials to assess its effectiveness in improving cardiac function by optimizing energy utilization within heart cells. By boosting cellular energy output, Imbria aims to provide treatments that can modify disease progression and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from conditions characterized by impaired cellular energy production, such as hypertrophic cardiomyopathy, and the physicians who treat them.
Features
- Ninerafaxstat: A novel therapeutic candidate designed to enhance cellular energy production.
- Clinical trials: Currently undergoing evaluation for the treatment of hypertrophic cardiomyopathy (HCM).
- Metabolic focus: Addresses energy deficits at the cellular level.